ACRV News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AC

Volume

253.24K

Next Earnings

November 12th

Loading chart

AC

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRV

Pay with—

Available Balance0.00

AC

Mkt Cap

$75.4M

Volume

253.24K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development OpportunitiesAcrivon Therapeutics announced preclinical data showing strong synergies between its lead assets ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) when combined with anti-PD-L1 checkpoint inhibitors and ADC payloads. The company will present three posters at the AACR 2026 Annual Meeting in San Diego, demonstrating potent efficacy and durable immune memory in combination therapies, supporting potential frontline clinical development opportunities.GlobeNewswire Inc. · Apr 17, 2026

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint InhibitorsAcrivon Therapeutics announced three poster presentations at the 2026 AACR Annual Meeting showcasing preclinical data demonstrating strong synergy of ACR-368 (CHK1/2 inhibitor) with Topoisomerase 1 inhibitor ADC payloads, and synergy of both ACR-368 and ACR-2316 (WEE1/PKMYT1 inhibitor) with immune checkpoint inhibitors. The data highlight the company's AP3 platform's ability to identify therapeutic candidates and combinations with clinical potential.GlobeNewswire Inc. · Mar 17, 2026

Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsightA comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.GlobeNewswire Inc. · Jul 15, 2025

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisAcrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.GlobeNewswire Inc. · Sep 14, 2024

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment ResearchAthira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.Zacks Investment Research · Jul 10, 2024

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC - Zacks Investment ResearchAstraZeneca's lung cancer drug Tagrisso has been approved by the European Commission for use in combination with chemotherapy as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer. The approval was based on positive data from the FLAURA2 study, which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy.Zacks Investment Research · Jul 5, 2024

SpringWorks (SWTX) Completes NDA Submission for MirdametinibSpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.Zacks Investment Research · Jul 2, 2024

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded UseThe CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.Zacks Investment Research · Jul 2, 2024

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD StudyBeam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.Zacks Investment Research · Jun 27, 2024

Corcept (CORT) Shares Rise 20% in Three Months: Here's WhyCorcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.Zacks Investment Research · Jun 26, 2024

to start trading

AC

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRV

Pay with—

Available Balance0.00

Your PositionYou don't own any ACRV yet.

Related Tickers

Earnings